Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,556.00GBp
11:28am BST
Change (% chg)

4.60 (+0.30%)
Prev Close
1,551.40
Open
1,551.80
Day's High
1,556.20
Day's Low
1,547.40
Volume
1,538,425
Avg. Vol
7,343,167
52-wk High
1,648.80
52-wk Low
1,408.80

Select another date:

Fri, May 17 2019

Photo

GSK and Novartis liniment marketing misled Australian consumers - court

SYDNEY The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday.

GSK and Novartis liniment marketing misled Australian consumers: court

SYDNEY The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday.

GSK and Novartis liniment marketing misled Australian consumers -court

SYDNEY, May 17 The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday.

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

UPDATE 1-GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

May 9 GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

GSK's 3-in-1 inhalable drug shows promise in asthma study

British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

GSK's 3-in-1 inhalable drug shows promise in asthma study

British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.

Select another date: